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INTRODUCTION
Various neoplasms, including thymus-related le-
sions, lymphomas and germ cell tumors, involve the
anterior mediastinum. Thymic epithelial tumors are
the most common type of thymus-related lesions.
Thymic epithelial tumors are classified in two ma-
jor groups, thymomas and thymic carcinomas, in the
latest World Health Organization (WHO) classifi-
cation (2004). There are various pathological types
of thymic epithelial tumors, and the clinical features
and prognosis associated with each tumor depend
on the pathological type. Furthermore, the WHO
histological classification and Masaoka staging, a
surgical staging system based on the presence of
invasion in the surrounding organs, closely corre-
late with prognosis. To differentiate and predict the
histology and initial staging of tumors, conducting
less invasive imaging evaluations prior to adminis-
tering any invasive procedures or treatments is im-
portant. CT and MRI are useful for evaluating the
morphological appearance of tumors and the pres-
ence of invasion in surrounding fat tissues or struc-
tures such as the pleura, lungs or vessels. However,
some findings are overlapping, which thus makes
it difficult to diagnose histological subtypes correctly.
On the other hand, fluoro-deoxy-glucose positron
emission tomography (FDG-PET) can provide use-
ful metabolic information regarding thymic lesions.
In this article, the available literature on the util-
ity of FDG-PET in the diagnosis of thymic epithe-
lial tumors is reviewed and the results of an inves-
tigation conducted in our institute are reported.
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Abstract : In this article, seven studies evaluating the utility of FDG-PET in the diagno-
sis of thymic epithelial tumors were reviewed and the results of an investigation conducted
in Tokushima University Hospital are reported. FDG accumulation of low-risk thymoma
is low, and FDG accumulation of thymic carcinoma is high. High-risk thymoma exhibits
various degrees of accumulation and a definite conclusion has not yet been reached ; how-
ever, overall, the higher the histological grade, the higher the FDG accumulation becomes,
suggesting that this is correlated to staging. Our data also support the previous reports.
FDG-PET may indicate lymph node metastasis and distant metastasis, which are some-
times difficult to detect using other modalities. When lymph node metastasis and/or dis-
tant metastasis are suspected in addition to thymic lesions, FDG-PET/CT, which allows
for searching of the entire body at once, is useful. FDG-PET/CT is effective for estimat-
ing histopathological malignancy and staging in the diagnosis of thymic epithelial tu-
mors and can be an important imaging test with high relevance to the prognosis of a pa-
tient. J. Med. Invest. 59 : 225-234, August, 2012
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THYMIC EPITHELIAL TUMORS
Histological classification (Table 1)
The World Health Organization (WHO) published
the histological classification in 1999. In this version,
thymomas were divided into five subtypes and thy-
mic carcinomas were classified as type C. The WHO
classification was renewed in 2004 and this version
of the classification is widely used today. In the 2004
classification, rare subtypes were added to tradi-
tional types, type C was removed and thymic carci-
nomas were classified in various subtypes, includ-
ing neuroendocrine epithelial tumors. Thymomas
were divided into type A and type B according to
the shape of the tumor cells and nuclei. Type B was
also subdivided in three subtypes, B1, B2 and B3,
according to the number of lymphocytes and the
atypia of the tumor cells. Type B1 is lymphocyte-
dominant and type B3 is epithelial component-
dominant. The grade of malignancy increases with
the progression of each subtype : A, AB, B1, B2,
B3. Thymic carcinomas were defined as all malig-
nant non-organotypic epithelial neoplasms except
germ cell tumors. Squamous cell carcinomas are the
most common type of thymic carcinomas. Thymic
epithelial tumors are divided into three subgroups
based on prognosis and WHO histological classifica-
tion : low-risk (LR), including types A, AB and B1 ;
high-risk (HR), including types B2 and B3 ; and thy-
mic carcinomas (CA).
Clinical staging
Masaoka staging is widely used to assess thy-
momas (Table 2) and is closely correlated with the
prognosis. Masaoka staging is based on the pres-
ence of invasion in the capsule or surrounding or-
gans, the existence of pleural or pericardial dissemi-
nation and the presence of lymphogenous or hema-
togenous metastasis. WHO TNM classification for
malignant thymic epithelial tumors was published
in 2009 (Table 3).
FDG-PET
Review of previous reports
The author searched the PubMed database insert-
ing the following key words : “thymus,” ”epithelial,”
“tumor,” “PET” and “FDG” and found seven stud-
ies evaluating the utility of FDG-PET in the diag-
nosis of thymic epithelial tumors. The author also
added the results of an investigation conducted in




Composed of a homogeneous population of neoplastic eplthelial cells having spindle and oval
shapes, lacking nuclear atypia, and accompanied by few or no non-neoplastic lymphocytes
Type AB Foci have the features of type A thymoma and are admixed with foci rich inl ymphocytes, withsharp or indistinct segregation of the two patterns
Type B1 Resembles the normal functional thymus in that it combines large expanses with an appearancepractically indistinguishable from normal thymic cortex with areas resembling thymic medulla
Type B2
High
Neoplastic epithelial component appears as scattered plump cells with vesicular nuclei and
distinct nucleoli among a predominant population of lymphocytes ; perivascular spaces are
common
Type B3
Predominantly composed of epithelial cells with a round or polygonal shape and exhibiting no
or mild atypia, admixed with a minor component of lymphocytes ; foci of squamous metaplasia
and perivascular spaces are common
Thymic carcinoma Exhibits clear -cut cytologic atypia and a set of cytoarchitectural features no longer specific tothymus but, rather, analogous to those seen in carcinomas of other organs
Table 2 : Masaoka staging system
Stage Description
I Encapsulated tumor without microscopic evidence of capsular invasion
II Microscopic or macroscopic invasion of the surounding fatty tissue or the mediastinal pleura
III Macroscopic invasion of neighboring organs, such as the pericardium, lung, or the great vessels
IVa Pericardial or pleural dissemination
IVb Lymph node or distant metastasis
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Tokushima University Hospital to this article.
A summary is shown in Table 4 (1-7). Three of
the seven articles grouped thymic epithelial tumors
into three subgroups (low-risk, high-risk and thy-
mic carcinomas) (1, 2, 4), three articles classified
thymic epithelial tumors into two subgroups (low-
risk and high-risk (types B2, B3 and thymic carci-
nomas)) (3, 5, 7) and one article grouped thymic
epithelial tumors into thymoma and thymic carci-
noma groups (6). Two articles used the T/M ratio
of maximum standardized uptake value (SUVmax)
to evaluate the degree of FDG uptake (2, 4). One
article reported the use of dual time-point, early and
delayed scans (3). Two articles mentioned the bio-
logic correlations between thymic epithelial tumors
and glucose transporters (Glut), hexokinase, hy-
poxia, angiogenesis and cell cycle regulators (4, 5).
Sung et al. classified 33 cases of thymic epithelial
tumors into low-risk (types A, AB and B1), high-
risk (types B2 and B3) thymoma, and thymic car-
cinoma, and investigated the FDG-PET/CT as well
as enhanced CT. The SUVmax of the low-risk and
high-risk groups was statistically significantly lower
than that of thymic carcinoma. FDG uptake pattern
and mediastinal fat invasion using enhanced CT was
useful for differentiating subgroups ; whereby, it was
determined that lymph node metastasis that could
not be indicated using enhanced CT was indicated
using PET/CT in 2 of 33 patients, and it was re-
ported that PET/CT was useful for differentiating
subgroups as well as the staging of thymic epithe-
lial tumors (1). Endo et al. divided 36 cases of thy-
mic epithelial tumors into 3 groups (low-risk, high-
risk and thymic carcinoma) in the same manner as
Sung et al. , and the SUVmax of the lesions with re-
spect to the mediastinal SUVmax was investigated
as a T/M ratio (ratio of the peak SUV of the tumor
to the mean SUV of the mediastinum at the level
of the aortic arch). As a result, it was reported that
3 groups may be differentiating using the T/M ratio,
and that PET was useful in the evaluation of thymic
epithelial tumors (2). Kaira et al. also evaluated thy-
mic epithelial tumors in 49 patients using the T/M
ratio, reporting that the T/M ratio was significantly
high in relation to the grade of malignancy. In this
paper, it is shown that the biologic mechanism of
the FDG uptake to thymic epithelial tumors is re-
lated to glucose metabolism, hypoxia, angiogenesis
Table 3 : TNM classification of Thymic Epithelial Tumors (WHO)
T factor
T1 : Tumor completely encapsulated
T2 : Tumor invades pericapsular connective tissue
T3 : Tumor invades into neighboring structures, such as pericardium, mediastinal pleura, thoracic wall, great vessels and lung
T4 : Tumor with pleural or pericardial dissemination
N factor
N0 : No lymph node metastasis
N1 : Metastasis to anterior mediastinal lymph nodes
N2 : Metastasis in other intrathoracic lymph nodes excluding anterior mediastinal lymph nodes
N3 : Metastasis in scalene and/or supraclavicular lymph nodes
M factor
M0 : No distant organ metastasis
M1 : Distant organ metastasis
Stage I T1 N0 MO
Stage II T2 N0 M0
Stage III T1 N1 M0
T2 N1 M0
T3 N0, 1 M0
Stage IV T4 Any N M0
Any T N2, 3 M0
Any T Any N M1
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Table 4 : A summary of seven articles. LR : Low-risk, HR : High-risk, CA : carcinoma, SUVmax : maximum standardized uptake value
Author Year No. of patients M/F year mean(range) group number Parameter Statistic analysis
Sung et al (1) 2006 33 15/18 55 (34 -68) SUVmax
LR 8 4.0 (0.42) LR vs HR : p=0.076
HR 9 5.6 (1.90) LR vs CA : p0.001
CA 16 10.5 (4.68) HR vs CA : p0.001
Endo et al (2) 2008 36 21/15 59 (32 -80) T/M ratio
LR 15 2.64 (0.78) LR vs HR : p=0.01
HR 10 4.29 (1.41) HR vs CA : p=0.01
CA 11 8.90 (3.62)
Inoue et al (3) 2009 46 29/17 58 (31 -75) early SUVmax





LR 3.4 HR vs LR : p=0.001
HR 7.4
Kaira et al (4) 2010 49 23/26 64 (32 -80) T/M ratio
LR 27 2.6 (0.9) LR vs HR : p=0.002
HR 11 4.3 (1.6) HR vs CA : p=0.008
CA 11 8.9 (3.6)
Nakajo et al (5) 2010 11 5/6 55 (41 -71) SUVmax
LR 6 3.05 (0.55) LR vs HR : p=0.008
HR 5 5.24 (2.44)
(B2, B3) 4
(CA) 1
Igai et al (6) 2010 13 6/7 59 (36 -78) SUVmax




Terzi et al (7) 2011 26 14/12 56 (34 -85) SUVmax
LR 14 4.0 (1.7) LR vs HR : p0.01
HR 12 14.1 (8.3)
(B2, B3) 4
(CA) 8 17.1(8.5)
Otsuka 2012 35 17/18 62 (27 -84) SUVmax
Thymoma 24 3.9 (2.0) LR vs CA ; p=0.007
LR 11 3.7 (1.8) HR vs CA : p=0.008
HR 13 4.0 (2.8) LR vs HR : p=0.99
CA 11 7.6 (3.7) Thymoma vs CA : p=0.0004
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and cell cycle regulator (4). Inoue et al. classified
46 cases into low risk tumors regarding type A,
AB, and B1 and high-risk tumors regarding type
B1,2 and thymic carcinoma, and reported the
SUVmax to be significantly higher in high risk tu-
mors. It has been determined that high risk and
low risk tumors may be differentiated with the high-
est precision when the cutoff value of SUVmax is
set at 4.5. Furthermore, in addition to the normal
imaging following an hour (early SUVmax), a de-
layed scan was conducted after 3 hours and the rate
of variability of SUVmax with delayed SUVmax,
early scan, and delayed scan were calculated as the
retention index (RI). Regardless of the type of tu-
mor, a higher value was shown in delayed SUVmax
than early SUVmax. It is reported that there was
no significant difference in RI between the low risk
group and the high risk group (3). Nakajo et al.
classified 11 patients into low risk tumors regarding
type A, AB, and B1 and high-risk tumors regarding
type B2, 3 and thymic carcinoma, and determined
that SUVmax exhibited a significantly higher value
in high risk than low risk tumors. Furthermore, it
is reported that FDG accumulation was highly cor-
related to Glut-1 and hexokinase II which promotes
glycolysis (5). Terzi et al. divided thymic epithelial
tumors into 2 groups of low risk and high risk, and
reported that there is a strong correlation between
SUVmax and the subgroup, as well as between
SUVmax and staging. Moreover, it has been deter-
mined that low risk and high risk cases may be
differentiated when the T/M ratio=2.75 is set as
the cut-off value (7). Igai et al. divided 13 patients
into the thymoma group and the thymic carcinoma
group, reporting that SUVmax was high in the thy-
mic carcinoma group among the two groups with a
statistical difference, and that FDG-PET was useful
in predicting the malignancy grade of the WHO (6).
INVESTIGATION IN TOKUSHIMA UNIVER-
SITY HOSPITAL
Patients and methods
This retrospective study was approved by the in-
stitutional review board of Tokushima University
Hospital. The research content was posted on the
information board at the entrance to the Imaging
Center of Tokushima University Hospital. Written in-
formed consent for FDG-PET/CT examination and
contrast enhanced CT was obtained from all pa-
tients.
Patient population
Thirty-five (17 males, 18 females ; age range 27
to 84 years, mean/SD : 61.6/14.3) patients with
FDG-positive and pathologically confirmed thymic
epithelial lesions who underwent FDG-PET/CT and
enhanced CT or non-enhanced diagnostic CT prior
to initial surgery, chemotherapy or radiation ther-
apy were enrolled in this study.
FDG-PET/CT
All FDG-PET/CT examinations were performed
before any treatments were administered. All pa-
tients were instructed to be fast for at least 6 hours
before FDG injection. The FDG-PET/CT images
were obtained one hour after the intravenous injec-
tion of 3.7 MBq/kg body weight of FDG. The pa-
tients’ blood glucose levels were confirmed to be
less than 150 mg/dl immediately prior to the ad-
ministration of FDG. Images were obtained using
a hybrid PET/CT scanner (Aquiduo, Toshiba, Ja-
pan) in 3-dimensional mode under free breathing.
The first images were localized images taken from
the top of the skull to the middle of the thigh fol-
lowed by CT images obtained with a 16-slice multi-
detector CT system. Emission data were acquired
in the caudo-cranial direction from the middle of the
thigh to the top of the skull. Two minutes of acqui-
sition time were used per bed position and most
patients required eight bed positions. Image recon-
struction was completed using an ordered subset
expectation maximization (OSEM) algorithm (two
iterations, 14 subsets). Attenuation-corrected emis-
sion data were obtained using filtered back projec-
tion CT data.
Chest CT
CT scans were performed primarily at Tokushima
University Hospital (32 patients), with the exception
of three patients. Isovoxel data were acquired using
16-slice multi-detector CT performed in our insti-
tution with 1 mm slice thickness and 2 ml/kg body
weight of iodine contrast material. Thirty enhanced
and five non-enhanced CT images were reviewed.
Scanning protocol such as scanning time and the
injection rate, dose and iodine concentration of the
contrast material were varied according to patient
condition, including patient body weight and renal
function.
Image interpretation
Two observers (board certificated physicians of
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diagnostic radiology/nuclear medicine/PET and di-
agnostic radiology/PET) reviewed the FDG-PET/
CT, enhanced and non-enhanced chest CT images.
The chest CT, PET and CT portions of the PET/
CT images were analyzed for attenuation correction
and anatomical recognition, and the fused PET/CT
images obtained in the axial, transverse and coronal
views were interpreted using Aquarias Net software
(TeraRecon). The maximum standardized uptake
value (SUVmax) of each lesion was measured to
evaluate the degree of FDG uptake.
The observers were given notice that the lesions
were FDG-positive thymic epithelial lesions ; how-
ever, they were blind to the following information :
final pathology, staging, age, gender, clinical symp-
toms, laboratory data and indication for FDG-PET/
CT examination. On the FDG-PET images, the de-
gree of FDG uptake and the presence of FDG-posi-
tive lymph nodes, dissemination, distant metastasis
and other primary lesions were evaluated. On the
CT images, the observers reviewed the size, con-
tour, shape, contrast enhancement pattern and ex-
istence of cystic or necrotic portions, calcification,
invasion of adjacent structures, dissemination, pleu-
ral effusion, pericardial effusion or lymphadenopathy
of each lesion.
Statistical analysis
The difference between the SUVmax and size of
each lesion were evaluated between subgroups us-
ing the Kruskal-Wallis test or t-test. A p value less
than 0.05 was considered to be statistically signifi-
cant.
RESULTS
A summary is shown in Table 5 and images of
type A, type B2 and thymic carcinomas are shown
in Figures 1-3.
(a) (b) (c)
Fig 1 : Thymoma type A, Masaoka stage I. (a) FDG-PET, (b) CT, (c) FDG-PET/CT. The lesion measures 34 mm and is oval -shaped
with a smooth surface. No necrosis or calcification are present. The SUVmax of the lesion is 2.7.
Table 5 : A summary of Tokushima University Hospital
LR HR CA
Masaoka stage
I 7 2 0
II 3 2 1
III 1 3 4
IVa 0 6 0
IVb 0 0 6
SUVmax
mean (SD) 3.7 (1.8) 4.0 (2.8) 7.6 (3.7)
size mm
mean (SD) 44 (19) 60 (34) 79 (32)
surface
smooth 10 5 3
irregular 1 8 8
shape
oval/round 7 3 2
lobulated 4 9 9
plaque 0 1 0
degeneratice change/necrosis
+ 6 8 11
- 5 5 0
calcification
+ 0 7 4
- 11 6 7
enhancement pattern on CT
heterogeneous 4 6 11
homogeneous 4 5 0
degree of enhancement
strong 2 1 5
slight-moderate 6 10 6
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(a) (b)
(c) (d)
Fig 2 : Thymoma type B2, Masaoka stage IVa. (a) FDG-PET, (b) CT, (c) FDG-PET/CT, (d) FDG-PET/CT. The lesion measures
41 mm and is lobulated with an irregular surface. No necrosis is present. Spotty calcification is observed. The SUVmax of the lesion
is 3.3. Pleural dissemination is also demonstrated (arrow in (d)). A reactive left hilar lymph node also shows FDG positive (a, c).
(a) (b)
Fig 3 : Thymic carcinoma, Masaoka stage IVb. (a) MIP (maximum intensity projection) image of FDG-PET, (b) FDG-PET/CT.
The lesion measures 57 mm and is lobulated with an irregular surface and necrosis. The lesion shows heterogeneous FDG uptake
with SUVmax 6.3. Liver metastases are also demonstrated (arrow in (a)).
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Fifteen patients showed symptoms of chest pain
or discomfort and two patients had blepharoptosis.
Twenty patients were incidentally found to have
abnormal anterior mediastinal lesions on chest X-
ray or chest CT. Pathologically, LR lesions were
found in 11 patients (type A : three patients, type
AB : three patients and type B1 : five patients), HR
lesions were found in 13 patients (type B1/2 : two
patients, type B2 : seven patients, type B2/3 : two
patients and type B3 : two patients) and CAs were
found in 11 patients. Two patients in the LR group
had lung adenocarcinomas, one patient in the HR
group had a large-cell lung carcinoma and one CA
patient had FDG-negative ground glass opacity on
CT that was confirmed to be a bronchoalveolar cell
carcinoma using video-assisted thoracic surgery.
Ten of 11 LR patients (91%) were found to be in
early Masaoka stages (I, II), whereas 10 of 11 CA
patients (91%) were found to be in advanced stages
(III, IV). Six of 11 (55%) CA patients were found to
have metastasis at the initial diagnosis. The Masaoka
stages of the HR lesions varied from early to ad-
vanced, with advanced stages dominating. Nine of
13 patients (70%) were diagnosed in stages III or IV.
The SUVmax values of the CA lesions were found
to be higher than those of the LR and HR lesions
(mean +/- SD : CA : 7.6 +/- 3.7, LR : 3.7 +/- 1.8 and
HR : 4.0 +/- 2.3). The differences between the val-
ues of the CA and LR lesions and the CA and HR
lesions were statistically significant (p=0.007 and
0.008, respectively), while the difference between
the values of the HR and LR lesions was not signifi-
cant (p=0.99). The difference between the values
of the thymoma (LR and HR) and thymic carcinoma
lesions was statistically significant (p=0.000482).
The LR lesions tended to be smaller and the CA
lesions tended to be larger with a statistically sig-
nificant difference (p=0.022). The LR lesions had
round/oval shapes with smooth margins, while the
CA lesions were lobulated with irregular margins.
The HR lesions had various shapes and margins
and tended to be lobulated with irregular margins.
Degenerative changes and necrosis were found in
all CA lesions and in six of 11 (55%) LR lesions and
eight of 13 (62%) HR lesions. Calcification was de-
tected in 31% of all lesions (11/35). No calcification
was detected in the LR lesions. The CA lesions
showed heterogeneous contrast enhancement on
CT, and the enhancement pattern varied in the LR
and HR lesions. The levels of anti-acetylcholine
receptor (anti-AchR) antibodies were analyzed in
a limited number of patients. Two of 10 (20%) LR
patients, one of nine (11%) HR patients and zero CA
patients were found to have elevated values. One
HR patient with an elevated anti-AchR level had
symptoms of myasthenia gravis.
DISCUSSION
The prognoses of patients with thymic epithelial
lesions are significantly correlated with two factors :
histological classification and clinical staging. The
WHO updated the histological classification to in-
clude five subtypes of thymomas and thymic carci-
nomas in 2004. It is reported that thymic epithelial
tumors found that the 5-year survival rate was 100%
in patients with type A tumors, 93% in patients with
type AB tumors, 89% in patients with type B1 tu-
mors, 82% in patients with type B2 tumors, 71% in
patients with type B3 tumors and 48.0% in patients
with thymic carcinomas (8). Therefore, patients with
low-risk thymomas have good prognoses, whereas
the prognoses of patients with high-risk thymomas
worsen with the progression from type B2 to type
B3 lesions and patients with thymic carcinomas
have poor prognoses. Masaoka’s criteria is widely
used to determine clinical staging. The criteria are
based on the presence of invasion in adjacent me-
diastinal adipose tissue or surrounding organs, and
Masaoka staging significantly correlates with prog-
nosis. The 20-year survival rate is 89% in patients
with stage I disease, 91% in patients with stage II dis-
ease, 49% in patients with stage III disease and 0% in
patients with stage VIa or VIb disease. There is a
significant divergence in prognosis between patients
with early (stages I, II) and advanced stage (stages
III, IV) disease. Therefore, predicting whether the
histological grade is low-risk, high-risk or carci-
noma and properly diagnosing the existence of inva-
sion to surrounding organs such as the pericardium,
great vessels or lungs are important before perform-
ing invasive procedures or administrating treatment.
CT and MRI are reported to be useful in evaluat-
ing thymic epithelial lesions (9-12). On CT, thy-
momas appear as round or oval-shaped soft tissue
masses with mild to moderate contrast enhance-
ment. Degenerative changes or necrosis present as
low density areas in the lesions. Calcification is de-
tected by the presence of high density spots. Jeong
reported that, on CT, lobulated contours were more
often seen in high-risk thymomas and thymic car-
cinomas (9). Sadohara reported that the presence
of irregular contours, necrosis or cystic components,
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heterogeneous enhancement and lymphadenopathy
are highly suggestive of thymic carcinomas (10).
In our study, the LR lesions tended to be smaller
than the CA lesions with a statistically significant
difference (p=0.005). The LR lesions were round/
oval-shaped with smooth margins, while the CA
lesions were lobulated with irregular margins. The
HR lesions had various shapes and margins and
tended to be lobulated with irregular margins. De-
generative changes and necrosis were found in all
CA lesions and in 50% of the LR lesions and seven
of 11 (64%) of the HR lesions. Calcification was de-
tected in 29% of all lesions (9/31). No calcification
was detected in the LR lesions. The CA lesions
showed heterogeneous contrast enhancement on
CT, while the enhancement pattern varied in the
LR and HR lesions. On MRI, thymomas show low
intensity on T1-weighted images, similar to that of
muscle, and relatively high intensity on T2-weighted
images. T2-weighted images show necrosis as high
intensity and internal septa as low intensity. T1-
weighted images show various signal patterns in
cystic regions ranging from low to high intensity,
reflecting the protein content and the presence of
hemorrhage. It is reported that MRI can differenti-
ate low-risk thymomas from high-risk thymomas
by depicting contours, capsules, septa and contrast
enhancement patterns. With respect to depicting
invasion outside of capsules, MRI is reported to be
superior to CT. Pathologically proving invasion in
surgical specimens is the most reliable method of
determining the presence of invasion, as CT and
MRI cannot detect microscopic invasion. In this
study, we underdiagnosed one thymic carcinoma
patient.
FDG-PET/CT is an advancing modality used to
evaluate tumor activity, glucose metabolism and
whole body morphology in a single session. It has
become an important noninvasive diagnostic tool in
the management of thymic lesions. FDG accumu-
lates in tumor cells according to viability or patho-
logical grading. Moreover, FDG accumulation is
affected by various factors, such as glucose metabo-
lism, hypoxia, angiogenesis. FDG accumulation
of low-risk thymoma is low, and FDG accumulation
of thymic carcinoma is high. High-risk thymoma
exhibits various degrees of accumulation and a defi-
nite conclusion has not yet been reached ; however,
overall, the higher the histological grade, the higher
the FDG accumulation becomes, suggesting that
this is correlated to staging. FDG-PET may indicate
lymph node metastasis and distant metastasis, which
are sometimes difficult to detect using other modali-
ties. When lymph node metastasis and/or distant
metastasis are suspected in addition to thymic le-
sions, it is not practical to histologically confirm the
metastatic lesions, and in such cases, FDG-PET/
CT, which allows for searching of the entire body
at once, is useful.
In summary, FDG-PET/CT is effective for esti-
mating histopathological malignancy and staging in
the diagnosis of thymic epithelial tumors and may
be an important imaging test with high relevance
to the prognosis of a patient.
Some portions of the data were presented at the
58th annual meeting of the Society of Nuclear
Medicine in 2011. The author greatly thanks “the
Nuclear Medicine Team” of Tokushima University
Hospital.
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